Sarepta Therapeutics (SRPT) Defended at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Price: $16.83 +1.94%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Join SI Premium – FREE
Cantor Fitzgerald analyst Alethia Young is reiterating their conviction on Sarepta Therapeutics (NASDAQ: SRPT) amid today's weakness.
The firm reiterated an Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple to launch AI features in China in December after regulatory delay - Bloomberg
- CrowdStrike (CRWD) PT Raised to $320 at Freedom Broker
- JD.com, Inc (JD) PT Lowered to $33 at US Tiger Securities
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Cantor Fitzgerald, Alethia YoungSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
